Simona Degli Esposti

3.4k total citations · 1 hit paper
30 papers, 1.1k citations indexed

About

Simona Degli Esposti is a scholar working on Molecular Biology, Ophthalmology and Hematology. According to data from OpenAlex, Simona Degli Esposti has authored 30 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 17 papers in Ophthalmology and 10 papers in Hematology. Recurrent topics in Simona Degli Esposti's work include Retinal Diseases and Treatments (14 papers), Multiple Myeloma Research and Treatments (10 papers) and Retinal Development and Disorders (10 papers). Simona Degli Esposti is often cited by papers focused on Retinal Diseases and Treatments (14 papers), Multiple Myeloma Research and Treatments (10 papers) and Retinal Development and Disorders (10 papers). Simona Degli Esposti collaborates with scholars based in United Kingdom, United States and France. Simona Degli Esposti's co-authors include Catherine Egan, Catey Bunce, Michel Michaelides, Tünde Pető, Philip Hykin, Robin Hamilton, Richard David Leslie, Andrew Kaines, Ranjan Rajendram and Samantha Fraser‐Bell and has published in prestigious journals such as Nature Medicine, Blood and PLoS ONE.

In The Last Decade

Simona Degli Esposti

30 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Partial recovery of visual function in a blind patient after optogenetic therapy

2021 424 citations José‐Alain Sahel, Élise Boulanger-Scemama et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simona Degli Esposti United Kingdom	12	509	410	409	304	157	30	1.1k
Rupert W. Strauß Austria	27	2.2k 4.4×	1.2k 2.9×	1.7k 4.1×	244 0.8×	14 0.1×	80	2.7k
Shin-ichi Manabe Japan	18	741 1.5×	590 1.4×	300 0.7×	71 0.2×	18 0.1×	42	1.1k
Manuel Simonutti France	14	530 1.0×	211 0.5×	509 1.2×	190 0.6×	10 0.1×	17	1.0k
Tjing‐Tjing Hu Belgium	14	147 0.3×	68 0.2×	253 0.6×	118 0.4×	18 0.1×	30	530
Kimberly K. Gokoffski United States	10	58 0.1×	41 0.1×	317 0.8×	116 0.4×	33 0.2×	34	612
Nadine S. Dejneka United States	17	484 1.0×	197 0.5×	1.1k 2.8×	332 1.1×	9 0.1×	21	1.4k
Umberto Di Vicino Italy	16	153 0.3×	75 0.2×	779 1.9×	189 0.6×	24 0.2×	22	949
Francis A. Billson Australia	17	934 1.8×	501 1.2×	379 0.9×	86 0.3×	6 0.0×	31	1.3k
Yousef Yafai Germany	20	464 0.9×	234 0.6×	497 1.2×	107 0.4×	6 0.0×	31	806
Fiona C. Mansergh Ireland	19	393 0.8×	157 0.4×	770 1.9×	260 0.9×	6 0.0×	36	1.2k

Countries citing papers authored by Simona Degli Esposti

Since Specialization

Citations

This map shows the geographic impact of Simona Degli Esposti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simona Degli Esposti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simona Degli Esposti more than expected).

Fields of papers citing papers by Simona Degli Esposti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simona Degli Esposti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simona Degli Esposti. The network helps show where Simona Degli Esposti may publish in the future.

Co-authorship network of co-authors of Simona Degli Esposti

This figure shows the co-authorship network connecting the top 25 collaborators of Simona Degli Esposti. A scholar is included among the top collaborators of Simona Degli Esposti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simona Degli Esposti. Simona Degli Esposti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Terpos, Evangelos, Suzanne Trudel, María‐Victoria Mateos, et al.. (2025). Practical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events. American Journal of Hematology. 100(10). 1839–1850. 2 indexed citations

Popat, Rakesh, Sagar Lonial, Peter M. Voorhees, et al.. (2023). Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma. Journal of the Advanced Practitioner in Oncology. 14(6). 503–518. 3 indexed citations

Sahel, José‐Alain, Élise Boulanger-Scemama, Angelo Arleo, et al.. (2021). Partial recovery of visual function in a blind patient after optogenetic therapy. Nature Medicine. 27(7). 1223–1229. 424 indexed citations breakdown →

Lonial, Sagar, Ajay K. Nooka, Praneetha Thulasi, et al.. (2021). Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer Journal. 11(5). 103–103. 47 indexed citations

Lonial, Sagar, Ajay K. Nooka, Praneetha Thulasi, et al.. (2021). P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 21. S149–S150. 1 indexed citations

Martel, Joseph N., Simona Degli Esposti, Élise Boulanger-Scemama, et al.. (2020). Optogenetics in the Clinic: PIONEER, a Phase 1/2a Gene Therapy Program for Non-Syndromic Retinitis Pigmentosa. Investigative Ophthalmology & Visual Science. 61(7). 4491–4491. 2 indexed citations

Popat, Rakesh, et al.. (2020). Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial. Haematologica. 105(5). e261–e263. 36 indexed citations

Patel, Praveen J., Hari Jayaram, Maria Eleftheriadou, et al.. (2020). Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial. Ophthalmology and Therapy. 9(3). 563–576. 2 indexed citations

Popat, Rakesh, Asim V. Farooq, Praneetha Thulasi, et al.. (2020). Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf). Blood. 136(Supplement 1). 43–44. 2 indexed citations

10.

Esposti, Simona Degli, Mohamed Rashad, Navjit Singh, et al.. (2020). Comparison of white light and scanning laser ophthalmoscopy ultra-widefield pseudocolor reflectance images in foveal hypoplasia. 61(7). 5304–5304. 2 indexed citations

11.

Müller, Philipp L., Tim Treis, Maximilian Pfau, et al.. (2020). Progression of Retinopathy Secondary to Maternally Inherited Diabetes and Deafness – Evaluation of Predicting Parameters. American Journal of Ophthalmology. 213. 134–144. 15 indexed citations

12.

Farooq, Asim V., Simona Degli Esposti, Rakesh Popat, et al.. (2020). Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmology and Therapy. 9(4). 889–911. 109 indexed citations

13.

Pető, Tünde, Catey Bunce, Wen Xing, et al.. (2020). Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa. British Journal of Ophthalmology. 104(9). 1203–1208. 14 indexed citations

14.

Okada, Mali, Anthony G. Robson, Catherine Egan, et al.. (2017). ELECTROPHYSIOLOGICAL CHARACTERIZATION OF MACULAR TELANGIECTASIA TYPE 2 AND STRUCTURE–FUNCTION CORRELATION. Retina. 38(1). S33–S42. 12 indexed citations

15.

Esposti, Simona Degli, et al.. (2016). Atrophy progression on autofluorescence in patients with Maternally Inherited Diabetes and Deafness (MIDD). 57(12). 1704–1704. 1 indexed citations

16.

Sallo, Ferenc B., Irene Leung, Simona Degli Esposti, et al.. (2016). Functional and structural measures of disease severity from a Phase 1 clinical trial in type 2 idiopathic macular telangiectasia.. 57(12). 4955–4955. 1 indexed citations

17.

Mehta, Hemal, Catherine Egan, Simona Degli Esposti, et al.. (2016). Natural history and effect of therapeutic interventions on subretinal fluid causing foveal detachment in macular telangiectasia type 2. British Journal of Ophthalmology. 101(7). 955–959. 12 indexed citations

18.

Esposti, Simona Degli, Tünde Pető, Irene Leung, Ferenc B. Sallo, & Catherine Egan. (2013). Severity And Progression Of Diabetic Retinopathy In Type 2 Macular Telangiectasia (MacTel). Investigative Ophthalmology & Visual Science. 54(15). 1531–1531. 3 indexed citations

19.

Sivaprasad, Sobha, Roxanne Crosby‐Nwaobi, Simona Degli Esposti, et al.. (2013). Structural and Functional Measures of Efficacy in Response to Bevacizumab Monotherapy in Diabetic Macular Oedema: Exploratory Analyses of the BOLT Study (Report 4). PLoS ONE. 8(8). e72755–e72755. 17 indexed citations

20.

Zati, A., et al.. (1998). Does total hip arthroplasty mean sensorial and proprioceptive lesion? A clinical study.. PubMed. 82(3). 239–47. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact